natgillin/translations-raw huggingface dataset:
For patients who are taking tenofovir disoproxil fumarate, if REYATAZ/ritonavir with both tenofovir disoproxil fumarate and an H2-receptor antagonist are co-administered, a dose increase of REYATAZ to 400 mg with 100 mg of ritonavir is recommended. 
Za bolesnike koji uzimaju tenofovirdizoproksilfumarat, ako se REYATAZ/ritonavir primjenjuju istovremeno s tenofovirdizoproksilfumaratom i antagonistom H2 receptora, preporučuje se povišenje doze lijeka REYATAZ na 400 mg sa 100 mg ritonavira.
Atazanavir, the active substance of REYATAZ, is excreted in human milk. 
Atazanavir, djelatna tvar lijeka REYATAZ izlučuje se u majčino mlijeko.
Voriconazole AUC ↓33% (↓42% Voriconazole Cmax ↓10% (↓22% ↓4%) Voriconazole Cmin ↓39% (↓49% ↓28%) 
Vorikonazol AUC ↓33% (↓42% Vorikonazol Cmax ↓10% (↓22% ↓4%) Vorikonazol Cmin ↓39% (↓49% ↓28%)
Co-administration of REYATAZ with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate or norethindrone has not been studied, and therefore should be avoided (see section 4.5). 
Nije ispitana istovremena primjena lijeka REYATAZ i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata ili noretindrona, te se stoga mora izbjegavati (vidjeti dio 4.5).
Concentrations of these antiarrhythmics may be increased when co-administered with REYATAZ. 
Koncentracije ovih antiaritmika mogu biti povišene kad se primjenjuju istovremeno s lijekom REYATAZ.
Treatment-Experienced REYATAZ Powder/ritonavir n=82 
Bolesnici koji su prethodno bili liječeni REYATAZ oralnim prašakom /ritonavirom n=82
Buprenorphine, once daily, stable maintenance dose (atazanavir 300 mg once daily with ritonavir 100 mg once daily) 
Buprenorfin, jedanput na dan, stabilna doza održavanja (atazanavir 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily) 
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI-jevi) Efavirenz 600 mg jedanput na dan (atazanavir 400 mg jedanput na dan s ritonavirom 100 mg jedanput na dan)
* When compared to REYATAZ 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. 
* Kad je uspoređivan s lijekom REYATAZ 300 mg/ritonavir 100 mg jedanput na dan, navečer, bez efavirenza.
The combination of rifampicin and REYATAZ is contraindicated (see section 4.3). 
Kombinacija rifampicina i lijeka REYATAZ je kontraindicirana (vidjeti dio 4.3).
Concomitant use of salmeterol and REYATAZ/ritonavir may result in increased cardiovascular adverse events associated with salmeterol. 
Istovremena primjena salmeterola i lijeka REYATAZ/ritonavira može rezultirati pojačanim kardiovaskularnim nuspojavama salmeterola.
a Intent-to-treat analysis, with missing values considered as failures. 
a Analiza prema planiranom liječenju, s time da su se vrijednosti koje su nedostajale smatrale neuspjehom.
Co-administration of lurasidone with REYATAZ is contrandicated as this may increase lurasidone-related toxicity (see section 4.3). 
Istodobna primjena lurasidona i lijeka REYATAZ je kontraindicirana, jer može povećati toksičnost povezanu s primjenom lurasidona (vidjeti dio 4.3.).
Bristol-Myers Squibb Pharma EEIG 
SQUIBB PHARMA EEIG
Table 9: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State atazanavir 300 mg with ritonavir 100 mg Pharmacokinetic Parameter 2nd Trimester (n=9) 
Tablica 9: Farmakokinetika atazanavira s ritonavirom u stanju dinamičke ravnoteže u trudnica zaraženih HIV-om u sitom stanju atazanavir 300 mg s ritonavirom 100 mg
Co-administration with REYATAZ/ritonavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5inhibitor-associated adverse events. 
Istovremena primjena s lijekom REYATAZ/ritonavirom može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s inhibitorom PDE5.
d Intent-to-treat analysis, with missing values considered as failures. 
d Analiza prema planiranom liječenju, s time da su se vrijednosti koje su nedostajale smatrale neuspjehom.
Co-administration of lurasidone with REYATAZ is contraindicated as this may incrrease lurasidone-related toxicity (see section 4.3) 
Istodobna primjena lurasidona i lijeka REYATAZ je kontraindicirana, jer može povećati toksičnost povezanu s primjenom lurasidona (vidjeti dio 4.3.)
Dose related asymptomatic prolongations in PR interval with REYATAZ have been observed in clinical studies. 
U kliničkim je ispitivanjima opaženo asimptomatsko produljenje PR intervala povezano s dozom lijeka REYATAZ.
Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving REYATAZ should be evaluated for alternative aetiologies. 
Potrebno je provjeriti alternativne uzroke povišenja jetrenih transaminaza koje može nastati uz povišenje bilirubina u bolesnika koji primaju REYATAZ.
BRISTOL-MYERS SQUIBB S.R.L. 
SQUIBB S.R.L.
Cholelithiasis has been reported in patients receiving REYATAZ (see section 4.8). 
U bolesnika koji primaju REYATAZ zabilježena je kolelitijaza (vidjeti dio 4.8).
HIV RNA <50 copies/ml, %a at least 5 to < 10 kg (REYATAZ 150 and 200 mg) at least 10 to < 15 kg at least 15 to < 25 kg at least 25 to < 35 kg 
HIV RNK <50 kopija/ ml, %a Najmanje 5 do < 10 kg (REYATAZ 150 i 200 mg)
Diltiazem 180 mg once daily (atazanavir 400 mg once daily) 
Diltiazem 180 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
Ethinyloestradiol 35 µg + norethindrone (atazanavir 400 mg once daily) 
Etinilestradiol 35 μg + noretindron (atazanavir 400 mg jedanput na dan)
Table 8: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State atazanavir 300 mg with ritonavir 100 mg Pharmacokinetic Parameter 2nd Trimester (n=9) 
Tablica 8: Farmakokinetika atazanavira s ritonavirom u stanju dinamičke ravnoteže u trudnica zaraženih HIV-om u sitom stanju atazanavir 300 mg s ritonavirom 100 mg
Ritonavir may decrease plasma levels of phenytoin and/or phenobarbital due to CYP2C9 and CYP2C19 induction. 
Zbog indukcije CYP2C9 i CYP2C19, primjena ritonavira može sniziti razine fenitoina i/ili fenobarbitala u plazmi.
Concentrations of these antiarrhythmics may be increased when co-administered with REYATAZ/ritonavir. 
Koncentracije ovih antiaritmika mogu biti povišene kad se primjenjuju istovremeno s lijekom REYATAZ/ritonavirom.
b Each sachet contains 50 mg of atazanavir. 
Jedna vrećica sadrži 50 mg atazanavira.
Concentrations of these immunosuppressants may be increased when co-administered with REYATAZ/ritonavir due to CYP3A4 inhibition. 
Koncentracije ovih imunosupresiva mogu biti povišene kad se primjenjuju istovremeno s lijekom REYATAZ/ritonavirom zbog inhibicije CYP3A4.
Haemophiliac patients: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors. 
Bolesnici s hemofilijom: U osoba s hemofilijom A i B liječenih inhibitorima proteaze zabilježeni su slučajevi pojačanog krvarenja, uključujući spontani nastanak kožnih hematoma i hemartroze.
Co-administration of voriconazole and REYATAZ with ritonavir is not recommended, unless an assessment of the benefit/risk justifies the use of voriconazole. 
Ne preporučuje se istovremena primjena vorikonazola i lijeka REYATAZ s ritonavirom, osim ako procjena omjera koristi i rizika opravdava primjenu vorikonazola.
ANTIFUNGALS Ketoconazole 200 mg once daily (atazanavir 400 mg once daily) 
ANTIMIKOTICI Ketokonazol 200 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
It inhibits CYP3A4. 
CYP3A4.
Co-administration of REYATAZ/ritonavir with quetiapine is contraindicated as may increase quetiapine-related toxicity. 
Istodobna primjena kvetiapina i lijeka REYATAZ/ritonavira je kontraindicirana jer REYATAZ može povećati toksičnost povezanu s primjenom kvetiapina.
Either one or three bottles of 30 hard capsules are provided in one carton. 
U jednoj kutiji nalazi se jedna ili tri bočice svaka s 30 tvrdih kapsula.
HIV RNA <400 copies/ml, %a at least 5 to < 10 kg (REYATAZ 150 and 200 mg) at least 10 to < 15 kg at least 15 to < 25 kg at least 25 to < 35 kg 
HIV RNK <400 kopija/ml, %a Najmanje 5 do < 10 kg (REYATAZ 150 i 200 mg)
Concentrations of these immunosuppressants may be increased when co-administered with REYATAZ due to CYP3A4 inhibition. 
Koncentracije ovih imunosupresiva mogu biti povišene kad se primjenjuju istovremeno s lijekom REYATAZ zbog inhibicije CYP3A4.
No dosage adjustments are needed for REYATAZ/ritonavir and fluconazole. 
Nisu potrebne prilagodbe doze flukonazola i lijeka REYATAZ/ritonavira.
200 mg (4 sachetsa) 
200 mg (4 vrećicaa)
REYATAZ is contraindicated in patients with severe hepatic insufficiency (see sections 4.2, 4.4 and 5.2). 
REYATAZ je kontraindiciran u bolesnika s teškom insuficijencijom jetre (vidjeti dijelove 4.2, 4.4 i 5.2).
Co-administration of REYATAZ/ritonavir with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate has not been studied, and therefore should be avoided. 
Istovremena primjena lijeka REYATAZ s ritonavirom i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata, nije ispitana i stoga je treba izbjegavati.
The dose and the number of REYATAZ oral powder sachets needed is determined based on weight (see section 4.2. 
Upute za uporabu Doza i broj potrebnih vrećica s REYATAZ oralnim praškom određuje se prema tjelesnoj težini (vidjeti dio 4.2.) 1. Prije miješanja vrećicu treba protresti da bi se prašak slegao.
Bepridil 
OPIOIDI
Nephrolithiasis has been reported in patients receiving REYATAZ (see section 4.8). 
U bolesnika koji primaju REYATAZ zabilježena je nefrolitijaza (vidjeti dio 4.8).
REYATAZ with ritonavir has not been studied in patients with hepatic impairment. 
REYATAZ s ritonavirom nije ispitan u bolesnika s oštećenjem funkcije jetre.
Treatment-Naive REYATAZ Powder/ritonavir n=52 
Boelesnici koji prethodno nisu bili liječeni s REYATAZ oralnim prašakom /ritonavirom n=52
300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil. 
S tenofovirdizoproksilfumaratom od 300 mg jedanput na dan (što odgovara 245 mg tenofoviridizoproksila)
The co-administration of REYATAZ/ ritonavir with abacavir is not expected to significantly alter the exposure of abacavir. 
Ne očekuje se da će istovremena primjena abakavira i lijeka REYATAZ/ritonavir značajno promijeniti izloženost abakaviru.
Gallbladder problems uncommonly happen in people taking REYATAZ. 
Manje često mogu se pojaviti problemi sa žučnim kamencima u osoba koje uzimaju lijek REYATAZ.
Study 045 is a randomised, multicenter trial comparing REYATAZ/ritonavir (300/100 mg once daily) and REYATAZ/saquinavir (400/1,200 mg once daily), to lopinavir + ritonavir (400/100 mg fixed dose combination twice daily), each in combination with tenofovir disoproxil fumarate (see sections 4.5 and 4.8) and one NRTI, in patients with virologic failure on two or more prior regimens containing at least one PI, NRTI, and NNRTI. 
U odraslih bolesnika koji su prethodno bili liječeni antiretrovirusnim lijekovima Ispitivanje 045 randomizirano je, multicentrično ispitivanje u kojem su REYATAZ/ritonavir (300/100 mg jedanput na dan) i REYATAZ/sakvinavir (400/1200 mg jedanput na dan) uspoređivani s lopinavirom + ritonavirom (400/100 mg, fiksna kombinacija doza, dvaput na dan), a svaka se od tih terapija primjenjivala u kombinaciji s tenofovirdizoproksilfumaratom (vidjeti dijelove 4.5 i 4.8) i jednim NRTI-jem u bolesnika u kojih je dva ili više prethodnih protokola s najmanje jednim inhibitorom proteaze, NRTI-jem i NNRTI-jem bilo virološki neuspješno.
REYATAZ 150 mg hard capsules 
REYATAZ 150 mg tvrde kapsule
250 mg (5 sachetsb) 
250 mg (5 vrećicaa)
HIV RNA <400 copies/ml, % a All patients 
HIV RNK <400 kopija/ml, % a Svi bolesnici
HIV RNA <50 copies/ml by select baseline PI substitutions,c % (responder/evaluabled) NA 
HIV RNK <50 kopija/ml prema početnim odabranim supstitucijama za rezistenciju na inhibitor proteaze,c % (bolesnici s odgovorom/bolesnici koje se moglo procijenitid)
Patients should be closely monitored for tenofovir disoproxil-associated adverse reactions, including renal disorders. 
Bolesnike treba pažljivo nadzirati zbog nuspojava tenofovira uključujući poremećaje bubrega.
SPECIAL STORAGE CONDITIONS Bottle pack: 
POSEBNE MJERE ČUVANJA Pakiranje s bocom
How to take REYATAZ 4. 
3. Kako uzimati REYATAZ
Chronic kidney disease in HIV-infected patients treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. 
Tijekom praćenja nakon stavljanja u promet, prijavljena je kronična bubrežna bolest u bolesnika zaraženih HIV-om, liječenih atazanavirom, sa ili bez ritonavira.
Co-administration with REYATAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-inhibitor-associated adverse events. 
Istovremena primjena s lijekom REYATAZ može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s inhibitorom PDE5.
NAME OF THE MEDICINAL PRODUCT REYATAZ 50 mg oral powder atazanavir 
NAZIV LIJEKA REYATAZ 50 mg oralni prašak atazanavir
Either one or three bottles of 60 hard capsules are provided in one carton. 
U jednoj kutiji nalazi se jedna ili tri bočice svaka sa 60 tvrdih kapsula.
Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 300 mg once daily with ritonavir 100 mg once daily) 
Didanozin (želučanootporne kapsule) 400 mg, jednokratna doza (atazanavir 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan)
Co-administration of REYATAZ/ritonavir and indinavir is not recommended (see section 4.4). 
REYATAZ/ritonavira i indinavira (vidjeti dio 4.4).
The Summary of Product Characteristics for ritonavir must be consulted before initiation of therapy with REYATAZ and ritonavir. 
Prije početka terapije lijekom REYATAZ i ritonavirom potrebno je pročitati Sažetak opisa svojstava lijeka za ritonavir.
In an open-label, randomised, comparative study following a 26- to 30-week induction phase with REYATAZ 300 mg + ritonavir 100 mg once daily and two NRTIs, unboosted REYATAZ 400 mg once daily and two NRTIs administered during a 48-week maintenance phase (n=87) had similar antiviral efficacy compared with REYATAZ + ritonavir and two NRTIs (n=85) in HIV infected subjects with fully suppressed HIV replication, as assessed by the proportion of subjects with HIV RNA < 50 copies/ml: 78% of subjects on unboosted REYATAZ and two NRTIs compared with 75% on REYATAZ + ritonavir and two NRTIs. 
U otvorenom, randomiziranom, usporednom ispitivanju provedenom nakon 26 do 30 tjednog uvodnog liječenja lijekom REYATAZ u dozi od 300 mg + ritonavirom u dozi od 100 mg jedanput na dan i dvama NRTI-ma u ispitanika s HIV infekcijom i potpuno suprimiranom replikacijom HIV-a, kombinacija nepojačanog lijeka REYATAZ u dozi od 400 mg jedanput na dan i dvaju NRTI-ja tijekom 48-tjedne faze održavanja (n=87) postigla je sličnu antivirusnu djelotvornost kao i REYATAZ
Ritonavir is administered immediately following REYATAZ powder administration. 
5. Ritonavir se primjenjuje odmah nakon primjene REYATAZ praška.
Study 138 is an international randomised, open-label, multicenter, prospective trial of 883 antiretroviral treatment naive patients comparing REYATAZ/ritonavir (300 mg/100 mg once daily) to lopinavir/ritonavir (400 mg/100 mg twice daily), each in combination with fixed dose tenofovir disoproxil fumarate/emtricitabine (300 mg/200 mg tablets once daily). 
U odraslih bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima Ispitivanje 138 međunarodno je, randomizirano, multicentrično, prospektivno ispitivanje otvorenog tipa u 883 bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima, u kojem se REYATAZ/ritonavir (300 mg/100 mg jedanput na dan) uspoređivao s lopinavirom/ritonavirom (400 mg/100 mg dvaput na dan), gdje su obje te kombinacije bile davane zajedno s fiksnom dozom tenofovirdizoprokislfumarata/emtricitabina (300 mg/200 mg tablete, jedanput na dan).
Carbamazepine should be used with caution in combination with REYATAZ/ritonavir. 
Karbamazepin se mora primjenjivati uz oprez u kombinaciji s lijekom REYATAZ/ritonavirom.
Co-administration of REYATAZ/ritonavir with products containing St. John's wort is contraindicated. 
Istovremena primjena lijeka REYATAZ/ritonavira i proizvoda koji sadrže gospinu travu je kontraindicirana.
Proton pump inhibitors Omeprazole 40 mg once daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily) 
Inhibitori protonske pumpe Omeprazol 40 mg jedanput na dan (atazanavir 400 mg jedanput na dan s ritonavirom 100 mg jedanput na dan)
Co-administration of REYATAZ and indinavir is not recommended (see section 4.4). 
Ne preporučuje se istovremena primjena lijeka REYATAZ i indinavira (vidjeti dio 4.4).
Atazanavir (am): 2 hr after omeprazole Atazanavir AUC ↓61% (↓65% ↓55%) Atazanavir Cmax ↓66% (↓62% ↓49%) Atazanavir Cmin ↓65% (↓71% ↓59%) 
Atazanavir AUC ↓61% (↓65% ↓55%) Atazanavir Cmax ↓66% (↓62% ↓49%) Atazanavir Cmin ↓65% (↓71% ↓59%)
The capsule shell and printing ink contain gelatine, shellac, ammonium hydroxide, simethicone, red iron oxide, black iron oxide, yellow iron oxide, propylene glycol, indigocarmin (E132) and titanium dioxide (E171). 
Ovojnica kapsule i tinta za označivanje sadrže želatinu, šelak, amonijev hidroksid, simetikon, crveni željezov oksid, crni željezov oksid, žuti željezov oksid, propilenglikol, indigokarmin (E132) i titanijev dioksid (E171).
Concomitant use of salmeterol and REYATAZ may result in increased cardiovascular adverse events associated with salmeterol. 
Istovremena primjena salmeterola i lijeka REYATAZ može rezultirati pojačanim kardiovaskularnim nuspojavama salmeterola.
Lamotrigine should be used with caution in combination with REYATAZ/ritonavir. 
Lamotrigin se mora primjenjivati uz oprez u kombinaciji s lijekom REYATAZ i ritonavirom.
Switching from REYATAZ oral powder to REYATAZ capsules is encouraged as soon as patients are able to consistently swallow capsules. 
Preproručuje se prijelaz s REYTAZ oralnog praška na REYATAZ kapsule čim su bolesnici mogu pozdanno progutati kapsule.
Co-administration of REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with increased grazoprevir concentrations (see section 4.3). 
Istodobna primjena lijeka REYATAZ s lijekovima koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvir/grazoprevir kontraindicirana je zbog povišene koncentracije grazoprevira i elbasvira i postoji rizik povišenja vrijednosti ALT-a zbog povećane koncentracije grazoprevira (vidjeti dio 4.3).
HCV Protease Inhibitors Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily) 
Inhibitori proteaze HCV-a Boceprevir 800 mg triput na dan (atazanavir 300 mg/ritonavir 100 mg jedanput na dan)
CD4 Mean Change from Baseline, cells/mm3 at least 5 to < 10 kg (REYATAZ 150 and 200 mg) at least 10 to < 15 kg at least 15 to < 25 kg at least 25 to < 35 kg 
CD4 prosječna promjena od početne vrijednosti, stanice/mm3 Najmanje 5 do < 10 kg (REYATAZ 150 and 200 mg)
Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1). 
Ritonavir se koristi kao pojačivač farmakokinetike atazanavira (vidjeti dijelove 4.5 i 5.1). (Vidjeti i "Prekid primjene ritonavira samo pod restriktivnim uvjetima" u dijelu 4.4).
Kidney stones uncommonly happen in people taking REYATAZ. 
Manje često mogu se pojaviti bubrežni kamenci u osoba koje uzimaju REYATAZ.
Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving REYATAZ. 
U bolesnika koji uzimaju REYATAZ može nastati hiperbilirubinemija (povišena razina bilirubina u krvi).
Your doctor will evaluate how severe your liver disease is before deciding whether you can take REYATAZ if you are taking any of these medicines: see also Other medicines and REYATAZ rifampicin (an antibiotic used to treat tuberculosis) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation) 
Liječnik će procijeniti koliko je teška Vaša bolest jetre prije nego što odluči možete li uzimati REYATAZ ako uzimate neki od ovih lijekova: vidjeti također Drugi lijekovi i REYATAZ rifampicin,(antibiotik za liječenje tuberkuloze) astemizol ili terfenadin (obično se primjenjuju za liječenje simptoma alergije i mogu se nabaviti bez recepta); cisaprid (primjenjuje se za liječenje želučanog refluksa, tj. žgaravice); pimozid (primjenjuje se za liječenje shizofrenije); kinidin ili bepridil (primjenjuju se za liječenje poremećaja srčanog ritma); ergotamin, dihidroergotamin, ergonovin, metilergonovin (primjenjuju se za liječenje glavobolje); i alfuzosin (primjenjuje se za liječenje povećanja prostate) kvetiapin (primjenjuje se za liječenje shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja), lurasidon (primjenjuje se za liječenje shizofrenije) lijekove koji sadrže gospinu travu (Hypericum perforatum, biljni pripravak)
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava:navedenog u Dodatku V.
uncommon: gynaecomastia 
manje često: ginekomastija
Coadministration with REYATAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism. 
REYATAZ može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s PDE5, uključujući hipotenziju, poremećaje vida i prijapizam.